This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Pinski, J. Articles by Isaacs, J. T. Search for Related Content PubMed PubMed Citation Articles by Pinski, J. Articles by Isaacs, J. T.

Therapeutic Implications of Enhanced G₀/G₁ Checkpoint Control Induced by Coculture of Prostate Cancer Cells with Osteoblasts¹

Johns Hopkins Oncology Center [J. P., A. P., J. T. I.], and Departments of Pathology [G. S. B.] and Urology [J. T. I.], Johns Hopkins School of Medicine, Baltimore, Maryland 21231

Osteoblastic metastases are common in lethal prostate cancer. Effective therapyfor bone metastases is lacking. Thus, developing an appropriate in vitro screening system is critical to prioritize which of the newly developed agents should undergo additional expensive and time-consuming in vivo evaluation in bone metastases animal models. In the past, such in vitro screening evaluated the response of prostate cancer cells to chemotherapeutic agents in monoculture without the presence of osteoblasts. In such monoculture, prostate cancer cells have a high (i.e., >90%) proliferative growth fraction. In contrast, the growth fraction (i.e., mean: 7.1 ± 0.8%; median: 3.1%) in 117 metastatic sites of prostate cancer obtained from 11 androgen ablation failing patients at "warm" autopsy was found to be >10-fold lower. To better mimic the lower growth fraction observed clinically, LNCaP human prostate cancer cells were cocultured with membrane-separated hFOB human osteoblasts. Such coculturing significantly lowered the growth fraction of the LNCaP cells (i.e., from >90 to <30%) without enhancing their low rate (i.e., <5%) of apoptosis. This lowering of the growth fraction was documented using flow cytometry, Ki-67 immunohistochemistry, and 5-bromo-2-deoxyuridine incorporation. Using RNase protection assays, it was documented that coculture with osteoblasts causes enhanced p53, p27, and p21 expression leading to a decrease in the number of LNCaP cells entering the cell cycle (i.e., enhanced number of LNCaP cells in G₀-G₁ and a decrease in S and G₂-M and thus the growth fraction). This osteoblast-induced enhanced G₀-G₁ checkpoint control affected the chemosensitivity of LNCaP cells. This was documented by coculturing LNCaP cells with hFOB cells to condition the medium for 3 days to lower the growth fraction to <30% before exposing the LNCaP cells for 48 h to various concentrations of Taxol, doxorubicin, or thapsigargin (TG). In standard high (i.e., >90%) growth fraction cultures (i.e., cultures in the absence of osteoblast-conditioned medium), there was a dose-dependent and significant (P < 0.05) increase in apoptosis of LNCaP cells exposed to Taxol or doxorubicin. In contrast, even the highest dose of Taxol (1 µM) did not enhance apoptosis of lower growth fraction LNCaP cells cultured in osteoblast-conditioned medium. Similarly, only the highest concentration of doxorubicin (1 µM) enhanced apoptosis in lower growth fraction cells. In contrast, 100 nM TG induced high levels of apoptosis in both lower and high-growth fraction LNCaP cultures. These results demonstrate that the osteoblast/LNCaP coculture system is a better in vitro screen than monoculture to identify proliferation-independent agents for the treatment of prostate cancer bone metastases, and TG is such an agent.

This article has been cited by other articles:

				S. S. Chandran, A. Nan, D. M. Rosen, H. Ghandehari, and S. R. Denmeade A prostate-specific antigen activated N-(2-hydroxypropyl) methacrylamide copolymer prodrug as dual-targeted therapy for prostate cancer Mol. Cancer Ther., November 1, 2007; 6(11): 2928 - 2937. [Abstract] [Full Text] [PDF]

				P. Mathew, P. F. Thall, C. D. Bucana, W. K. Oh, M. J. Morris, D. M. Jones, M. M. Johnson, S. Wen, L. C. Pagliaro, N. M. Tannir, et al. Platelet-Derived Growth Factor Receptor Inhibition and Chemotherapy for Castration-Resistant Prostate Cancer with Bone Metastases Clin. Cancer Res., October 1, 2007; 13(19): 5816 - 5824. [Abstract] [Full Text] [PDF]

				Z Wu, K. McRoberts, and D Theodorescu The role of PTEN in prostate cancer cell tropism to the bone micro-environment Carcinogenesis, July 1, 2007; 28(7): 1393 - 1400. [Abstract] [Full Text] [PDF]

				R. B. Shah, R. Mehra, A. M. Chinnaiyan, R. Shen, D. Ghosh, M. Zhou, G. R. MacVicar, S. Varambally, J. Harwood, T. A. Bismar, et al. Androgen-Independent Prostate Cancer Is a Heterogeneous Group of Diseases: Lessons from a Rapid Autopsy Program Cancer Res., December 15, 2004; 64(24): 9209 - 9216. [Abstract] [Full Text] [PDF]

				S. Janssen, C. M. Jakobsen, D. M. Rosen, R. M. Ricklis, U. Reineke, S. B. Christensen, H. Lilja, and S. R. Denmeade Screening a combinatorial peptide library to develop a human glandular kallikrein 2-activated prodrug as targeted therapy for prostate cancer Mol. Cancer Ther., November 1, 2004; 3(11): 1439 - 1450. [Abstract] [Full Text] [PDF]

				S. R. Denmeade, C. M. Jakobsen, S. Janssen, S. R. Khan, E. S. Garrett, H. Lilja, S. B. Christensen, and J. T. Isaacs Prostate-Specific Antigen-Activated Thapsigargin Prodrug as Targeted Therapy for Prostate Cancer J Natl Cancer Inst, July 2, 2003; 95(13): 990 - 1000. [Abstract] [Full Text] [PDF]

				J. Y. Ahn, E. Y. Jung, H. J. Kwun, C.-W. Lee, Y.-C. Sung, and K. L. Jang Dual effects of hepatitis B virus X protein on the regulation of cell-cycle control depending on the status of cellular p53 J. Gen. Virol., November 1, 2002; 83(11): 2765 - 2772. [Abstract] [Full Text] [PDF]

				J. Pinski, A. Weeraratna, A. R. Uzgare, J. T. Arnold, S. R. Denmeade, and J. T. Isaacs Trk Receptor Inhibition Induces Apoptosis of Proliferating but not Quiescent Human Osteoblasts Cancer Res., February 1, 2002; 62(4): 986 - 989. [Abstract] [Full Text] [PDF]